The Biologics Price Competition and Innovation Act was signed into existence in 2010 to help drive down the price of biologics by encouraging the development of competitive biosimilars. Since then, there have been many questions around the BPCIA and the provisions for asserting and challenging relevant patents. One example is the recent Federal Circuit case, Sandoz v. Amgen, which could have significant implications for future patent challenges associated with biosimilars. Finnegan attorneys Sanya Sukduang and Jonathan R. Davies, Ph.D. discuss the current legal and regulatory landscape for biosimilars.
Click here to view the podcast.